Effects of Oveporexton, an Orexin Receptor 2–Selective Agonist, on Cognition in Narcolepsy Type 1

What are the effects of oveporexton, an oral orexin receptor 2 (OX2R) agonist, on cognitive symptoms in narcolepsy type 1 (NT1)?This secondary analysis of exploratory outcomes from a phase 2 randomized clinical trial reports moderate- to large-magnitude effects of oveporexton on cognitive measures in adults with NT1.These findings suggest that OX2R stimulation with oveporexton can improve cognitive symptoms in adults with NT1.

Corresponding Author: Brian T. Harel, PhD, JD, Takeda Development Center Americas Inc, 500 Kendall St, Cambridge, MA 02142 (brian.harel@takeda.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.